Este estudio tiene como objetivo explorar la eficacia y seguridad de un tratamiento combinado que incluye el suplemento Xtressé™ y un suero para promover el crecimiento del cabello en mujeres que sienten que tienen el cabello fino. Las mujeres entre las edades de 28 a 65 años que han notado una disminución en el grosor de su cabello son elegibles para participar. Esta investigación es importante porque podría proporcionar una nueva solución para las mujeres que experimentan este problema común, mejorando potencialmente su calidad de vida y autoestima si el tratamiento resulta exitoso. Los participantes en el estudio deberán proporcionar información personal y médica, someterse a ciertos exámenes médicos y seguir directrices específicas durante el estudio. Aplicarán el suero y consumirán un tratamiento en gomitas cada día, llevando un diario de su rutina de tratamiento. Las evaluaciones clínicas incluirán fotografías y mediciones de la densidad del cabello, centrándose en un área marcada en el cuero cabelludo. El estudio también requiere que los participantes eviten otros tratamientos capilares y mantengan su rutina actual de cuidado del cabello. Los participantes son libres de abandonar el estudio en cualquier momento si así lo desean.
Inclusion Criteria: * Female adults between 28-65 years of age with consistent self-perceived thinning hair. * Ludwig Scale I or II (mild to moderate thinning hair loss), assessed clinically. * Fitzpatrick Skin Types I to VI. * Agree to maintain their current diet, medications, exercise routines, hair shampooing, and color treatment frequency for the duration of the study. * Ability and willingness to comply with the study protocol including regular visits and product application. * Written informed consent obtained, including written consent to allow photographs to be used as part of the study data and documentation. * For females of childbearing potential, a negative pregnancy test at screening and commitment to effective contraception throughout the study (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy) to avoid pregnancy-related hormonal changes affecting hair density. Exclusion Criteria: * Pregnant or lactating or planning to become pregnant. * Changes in hormonal therapy within 6 months prior to enrollment and throughout the study. * Use of other medical hair loss treatments (e.g., Minoxidil, Dutasteride, Finasteride, laser or light therapy) within 3 months prior to study start and throughout the study. * Micro-needling, PRP, or any other physical treatment modality on the scalp (within 6 months prior to study start and throughout the study). * Use of GLP-1 inhibitors (e.g., Semaglutide) within 6 months prior to study start and throughout the study. * Known uncontrolled health conditions (e.g., thyroid disease, anemia) that could confound study outcomes. * Known sensitivity to any of the ingredients in the study medication. * In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study. * Subject has any conditions, findings in history, physical exam or laboratory assessments, which in the opinion of the investigator, would exclude the subject from continuing in this study. * Treatment with an experimental drug, biologic or device within 12 weeks of the screening visit.
están designados en este estudio
de ser asignado al grupo placebo